Researchers at Fundació Puigvert reduce the size of kidney tumors in tuberous sclerosis by more than 50%

  • The internal bleeding of these tumors poses a life risk for patients with this disease.
  • The Renal Research Network (REDinREN) and the Spanish Association of Patients with Tuberous Sclerosis have played a fundamental role in the study.

Barcelona, January 8, 2012.-A team of researchers from the Fundació Puigvert, belonging to the Renal Research Network (REDinREN), have managed to reduce the size of bleeding renal tumors by more than 50% in tuberous sclerosis without using surgery. Tuberous sclerosis is a hereditary disease, and its most common renal manifestation is the so-called renal angiomyolipomas, non-cancerous tumor masses implanted in the kidney.

The main danger of these benign tumors is bleeding, which can pose a life risk for the patient. Until now, there was no specific treatment for the disease, and surgery or embolization was used to avoid the risk of bleeding. However, these interventions reduced the amount of functioning kidney tissue, leading to a decline in renal function and the possible consequences this may entail. From now on, and thanks to the research conducted over two years by scientists from the Fundació Puigvert, tuberous sclerosis can be treated with a medication.

Coordinated by Dr. Roser Torra, researchers from the Fundació Puigvert who belong to REDinREN, and in close collaboration with the Spanish Association of Patients with Tuberous Sclerosis, have developed a clinical trial, funded by the Carlos III Health Institute, with 17 patients suffering from this rare disease who presented renal angiomyolipomas. The participants were treated for 2 years with rapamycin, an immunosuppressant commonly used to prevent organ transplant rejection. Due to the infrequent nature of the disease, the sample of 17 patients from across the Spanish geography makes the trial the largest conducted to date, both in terms of the number of patients and its duration.

The results from Dr. Roser Torra’s team, published in the journal Orphanet Journal of Rare Diseases, show that the average reduction in the volume of angiomyolipomas after 6 months was 55%. Furthermore, the reduction is maintained over time. The mechanism for achieving this reduction is that rapamycin inhibits the mTOR protein. In tuberous sclerosis, there is a permanent activation of mTOR, a protein that promotes the constant formation of blood vessels (angiogenesis) and cellular proliferation. mTOR inhibitors counteract the deleterious effect of this protein. As explained by Dr. Roser Torra, “this discovery opens the door, for the first time, to non-invasive specific treatment for this minority disease”. The main problem in tuberous sclerosis is not the mere presence of angiomyolipomas, but the risk of bleeding that this entails and that, as highlighted by the study director, “can endanger the patient’s life“. Therefore, the 55% reduction in tumor size is very beneficial, as it significantly reduces the risk of bleeding.

The research is part of an area of great interest for the Fundació Puigvert, hereditary kidney diseases, and is led by one of the most recognized experts in the field, Dr. Roser Torra. The research also involved Dr. Cristina Cabrera and the Radiology Service (Dr. Teresa Martí and Dr. Violeta Català), who enabled the volumetric assessment of renal lesions through nuclear magnetic resonance.